Frazier closes 12th fund in 30 years, with $617M to bet on cell/gene therapy, Big Pharma spinoffs and more
The team at Frazier Healthcare did a number of deals that exemplified its wide-ranging strategy in 2019: Tachi Yamada worked with gene therapy pioneer Jim Wilson to launch Passage Bio; Mike Gallatin sold Mavupharma and its STING-targeted small molecule to AbbVie; and Bhaskar Chaudhuri flipped Arcutis to an IPO just months after introducing it to the world via a crossover round close to $100 million. They’re now kicking off 2020 with a new, bigger fund that will give them firepower to do more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.